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susceptibility to NK cell-mediated lysis was affected. 
A single knockdown of HSF1 by shRNA decreased 
the surface expression of MICB but not that of MICA, 
and thereby, the NK cell-mediated lysis was only par-
tially blocked. In contrast, NZ28 completely blocked the 
MICA/B membrane expression on tumor cells and thereby 
strongly inhibited the NK cell-mediated cytotoxicity. This 
effect might be explained by a simultaneous inhibition of 
the transcription factors HSF1, Sp1 and NF-κB by NZ28. 
These findings suggest that new anticancer therapeutics 
should be investigated with respect to their effects on the 
innate immune system.
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Abstract The activity of natural killer (NK) cells is reg-
ulated by activating and inhibiting receptors, whereby the 
C-type lectin natural killer group 2D (NKG2D) receptor 
serves as the major activating receptor on NK cells which 
recognizes major histocompatibility class I chain-related 
proteins A and B (MICA/B). The MICA/B expression has 
been described to be regulated by the transcription fac-
tor heat shock factor 1 (HSF1). Inhibition of heat shock 
protein 90 (Hsp90) is known to induce the heat shock 
response via activation of HSF1 which is associated with 
tumor development, metastasis and therapy resistance and 
also with an increased susceptibility to NK cell-medi-
ated lysis. Therefore, we compared the effects of Hsp90 
inhibitor NVP-AUY922, HSF1 inhibitor NZ28 and HSF1 
knockdown on the sensitivity of lung (H1339) and breast 
(MDA-MB-231, T47D) cancer cells to NK cell-mediated 
cytotoxicity and the expression of the NKG2D ligands 
MICA/B. Although NVP-AUY922 activates HSF1, nei-
ther the MICA/B surface density on tumor cells nor their 
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Introduction
Inhibition of heat shock protein 90 (Hsp90) which pro-
motes tumor cell survival and proliferation by stabilizing 
multiple oncogenic client proteins is a promising concept to 
overcome resistance of tumor cells to anticancer therapies. 
Numerous inhibitors of Hsp90 are currently tested in clini-
cal trials. A negative side effect of Hsp90 inhibition is the 
activation of heat shock factor 1 (HSF1) which induces the 
expression of other cytoprotective stress proteins includ-
ing Hsp70. Consequently, inhibition of Hsp70 or HSF1 has 
been shown to improve the anticancer effectivity of Hsp90 
inhibitors [1–5]. With respect to ionizing irradiation, a 
simultaneous treatment of tumor cells with the HSF1 inhib-
itor NZ28 [5] and the Hsp90 inhibitor NVP-AUY922 has 
been shown to potentiate the radiosensitizing effect medi-
ated by NVP-AUY922 alone (unpublished data). Herein, 
we study how modulators of the heat shock response can 
affect natural killer (NK) cell-mediated immunity. The 
cytolytic activity of NK cells is regulated by a fine bal-
ance of activating and inhibitory NK cell receptors. Among 
others, the C-type lectin natural killer group 2D receptor 
(NKG2D) acts as an activating receptor which recognizes 
the major histocompatibility class I chain-related proteins 
A and B (MICA/B). An enhanced sensitivity of tumor 
cells to NK cell-mediated lysis has been attributed to an 
increased membrane expression density of the NKG2D 
ligands MICA and MICB [6–9]. Vice versa, a reduced 
MICA/B membrane expression on tumor cells impairs 
the recognition by NK cells and promotes tumor immune 
escape [10]. The molecular mechanisms that regulate the 
expression of MICA/B on tumor cells are not completely 
understood. In the promoter regions of MICA and MICB, 
heat shock elements (HSE) which are similar to those of 
the hsp70 genes have been found [11]. Stress such as heat 
shock induces the binding of the transcription factor HSF1 
to the HSE in the promoter region of MICA/B and thus up-
regulates mRNA and protein expression of MICA/B [12, 
13]. Inhibitors of Hsp90 which are also known to activate 
HSF1 increase the expression of MICA/B in a variety of 
multiple myeloma cells [6].
However, besides HSF1, other factors such as the tran-
scription factor SP1 which binds constitutively to the 
MICA/B promoter [12] have been described to participate 
in the transcriptional regulation of MICA/B. Histone dea-
cetylase inhibition (HDAC) can increase the binding of 
HSF1 and SP1 to the promoter of MICA/B and thus results 
in an increased membrane MICA/B expression [8, 14]. In 
endothelial cells, a treatment with TNF-α induces binding 
of the transcription factor NF-κB to the MICA promoter and 
thereby causes an up-regulated expression of MICA [15].
In the present study, we were interested to analyze the 
effects of HSF1 activation (Hsp90 inhibitor NVP-AUY922) 
and inhibition (NZ28, HSF1 knockdown) in different 
human cancer cells on the NK cell ligands MICA/B and 
its consequences on NK cell-mediated lysis. Our data dem-
onstrate that Hsp90 inhibition alters neither the MICA/B 
surface density nor the sensitivity of the tumor cells to 
NK cell-mediated lysis. A knockdown of HSF1 decreases 
the membrane expression of MICB but not that of MICA, 
whereas a treatment with NZ28 inhibits the expression 
of both, MICA and MICB on the surface of the investi-
gated tumor cells. In line with these findings, the loss of 
MICA and MICB on NZ28-treated tumor cells resulted in 
a complete inhibition of the NK cell-mediated cytotoxicity, 
whereas down-regulation of MICB by HSF1 knockdown 
resulted in a partial reduction in lysis mediated by NK 
cells. We also could show that NZ28 inhibits not only HSF1 
but also other transcription factors such as NF-κB and Sp1 
which are responsible for the expression of MICA/B.
Materials and methods
Reagents
10 mM stock solutions of NZ28 (J. Yaglom and M. Sher-
man; Boston University School of Medicine, USA) and 
NVP-AUY922 (Novartis) were prepared in 100 % DMSO. 
Dilutions were performed in PBS. A vehicle control with 
the respective amount of DMSO diluted in PBS was tested 
in all experiments to exclude an effect of DMSO itself 
(maximal 0.2 %).
Cells and cell culture
The human lung (H1339) and breast (MDA-MB-231, 
T47D) cancer cell lines were cultured as described previ-
ously [16, 17]. Cells were routinely checked for myco-
plasma contamination. The authenticity of the cell lines 
was tested by the DSMZ (German collection of microor-
ganisms and cell cultures).
Retroviral vectors and infection
For knockdown of HSF1, RNAi-Ready pSIREN-RetroQ 
vector with puromycin resistance (BD Biosciences) was 
used. Target sequence for HSF1 small interfering RNA was 
5′-TATGGACTCCAACCTGGATAA-3′ [5]. Retroviruses 
were produced by transfection of Phoenix cells with pSI-
REN-RetroQ/HSF1 shRNA (shHSF1) or pSIREN-RetroQ 
(control) (provided by J. Yaglom and M. Sherman, Boston 
University School of Medicine, USA) using Ca phosphate. 
Tumor cells were infected with virus containing superna-
tants in the presence of 10 µg/ml polybrene. Selection was 
performed with 2 µg/ml puromycin.
601Cancer Immunol Immunother (2015) 64:599–608 
1 3
Western blot analysis and ELISA
Cells were lysed in TBST buffer as described previously 
[18]. The protein content in the cell lysates was determined 
using the BCA™ Protein Assay Kit (Pierce). On immuno-
blots, proteins were detected with antibodies against HSF1 
(ADI-SPA-901; Enzo Life Sciences), HSF1 phospho S326 
(pHSF1) (ab76076; abcam), Hsp70 (ADI-SPA-810; Enzo 
Life Sciences) and β-actin (A5316; Sigma-Aldrich).
MICA and MICB concentrations in the cell lysates were 
measured by ELISA (R&D Systems), and the concentra-
tions were calculated relative to the total protein content of 
each sample.
Luciferase assay
Cells were transfected with an inducible transcription fac-
tor-responsive (HSF1, Sp1, NF-κB) firefly luciferase con-
struct (Qiagen). The luciferase activity was measured using 
the Dual-Glo Luciferase assay system (Promega). A consti-
tutive Renilla luciferase construct served as an internal con-
trol for normalizing transfection efficiencies, cell viability 
and cell numbers.
Flow cytometry
Cells were incubated with the APC-conjugated MICA 
(clone 159227, FAB1300A, R&D Systems) and MICB 
antibodies (clone 236511, FAB1599A, R&D Systems) or 
the corresponding isotype-matched control antibody (clone 
133303, IC0041A, R&D Systems) for 30 min at 4 °C. Dead 
cells were stained with propidium iodide, and only viable 
cells were analyzed on a FACSCalibur flow cytometer (BD 
Biosciences).
NK cell isolation
NK cells were generated by a CD3/CD19 depletion of 
PBMCs from healthy human volunteers using a magnetic 
separation method (Miltenyi Biotec). The purity of NK 
cells (89.9 % of lymphocytes) was determined by flow 
cytometry with antibodies against CD19 (#555413, BD 
Biosciences), CD3 (#345766, BD Biosciences) and CD56 
(#345811, BD Biosciences).
NK cell cytotoxicity
NK cells were stimulated with 100 IU/ml IL-2 (Novartis) 
for 4 days. Activation of NK cells was checked by flow 
cytometry with antibodies against CD94 (#555888, BD 
Biosciences), NKG2D (FAB139P, R&D Systems) and 
CD56 (#345811, BD Biosciences). Their cytotoxic activ-
ity against differentially pre-treated tumor cells was 
determined either by europium or by CD107 degranulation 
assay. During the co-incubation of tumor and NK cells, no 
drugs were added.
For the europium assay, the tumor cells were labeled 
with BATDA (Perkin Elmer) and then co-incubated with 
NK cells at different ratios in a V-bottom 96-well plate in 
200 µl-medium. After a 4-h co-incubation period at 37 °C, 
25 µl of supernatants were transferred into ELISA plates 
containing 200 µl europium solution (Perkin Elmer). The 
time-resolved fluorescence was measured using a Victor X4 
plate reader (Perkin Elmer).
In the degranulation assay, the cytotoxicity of NK cells 
was determined by measuring the cell surface expression 
of the lysosomal marker, CD107a, which correlates with 
NK cell cytotoxicity [19]. Tumor cells were mixed with 
NK cells at a ratio of 1:1 in a U-bottom 96-well tissue cul-
ture plate. Anti-CD107a-FITC (#555800, BD Biosciences) 
or the isotype-matched control antibody (#555748, BD 
Biosciences) was added. After 1 h, GolgiStop™ (BD Bio-
sciences) was added and after a co-incubation period of 
3 h, the cells were stained with anti-CD3-PerCP (#345766, 
BD Biosciences) and anti-CD56-APC (#555518, BD 
Biosciences) antibodies. The CD107a expression on the 
CD3−CD56+ NK cell population was determined by flow 
cytometry.
Statistics
Statistical analysis was performed using SPSS 18.0.2 soft-
ware (IBM). The unpaired Student’s t test was used to 
evaluate significant differences (*p ≤ 0.05, **p ≤ 0.01, 
***p ≤ 0.001).
Results
NZ28 impairs susceptibility of tumor cells to NK 
cell-mediated lysis
To investigate whether inhibitors of the stress response can 
modulate the sensitivity of human tumor cells to NK cell-
mediated cytotoxicity, HSF1 inhibitor NZ28 and/or Hsp90 
inhibitor NVP-AUY922-treated tumor cells were used 
as target cells for IL-2 (100 IU/ml)-activated NK cells. A 
successful stimulation of purified NK cells was shown by 
an up-regulated cell surface density of the NK cell mark-
ers CD94, CD56 and NKG2D (Fig. 1a) [20]. The cyto-
toxic activity of NK cells against H1339 (lung) and MDA-
MB-231 (breast) cancer cells was determined by measuring 
the expression of the lysosomal marker CD107a [6, 19]. 
As shown in Fig. 1b, the NK cell-mediated cytotoxicity 
against H1339 and MDA-MB-231 tumor cells that were 
treated with 2 or 20 µM NZ28 was significantly reduced 
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compared to untreated tumor cells (Fig. 1b). Treatment 
of tumor cells with 100 nM NVP-AUY922 alone did not 
affect the NK cell-mediated cytotoxicity, and a combined 
treatment with NZ28 and NVP-AUY922 did not reverse the 
immunosuppressing effect of NZ28. Similar findings were 
observed in another breast cancer cell line (T47D, supple-
mentary Fig. 1a). A direct drug-induced cytotoxicity could 
be excluded since the drug concentrations which were used 
in the cytotoxicity assays did not affect cell viability of the 
tumor cells (supplementary Figs. 1b, 2).
NZ28 suppresses the expression of activating NK cell 
ligands MICA and MICB
Hsp90 inhibitors such as NVP-AUY922 are known to acti-
vate HSF1, whereas NZ28 has been shown to inhibit the 
heat shock response by reducing the HSF1 activity [5, 21]. 
As HSF1 has been described to regulate the transcription of 
the NK cell ligands MICA and MICB [12, 13], we investi-
gated whether treatment of tumor cells with NZ28 and/or 
NVP-AUY922 alters the cell surface density [mean fluores-
cence intensity (MFI)] of the NK cell ligands MICA and 
MICB on tumor cells.
To test whether detaching adherent tumor cells with 
trypsin is suitable to measure the MICA/B membrane 
expression, the surface expression of MICA/B on cells 
that were detached with trypsin and accutase was com-
pared by FACS analysis. Accutase has been described 
to perform exceptionally well in detaching cells without 
altering the membrane expression of MICA/B [22]. As no 
differences were observed (supplementary Fig. 3), tumor 
cells treated for 24 h with NZ28 and/or NVP-AUY922 
were detached with trypsin and the MICA/B membrane 
expression was determined by FACS analysis. Repre-
sentative flow cytometric histograms are shown in Fig. 1c 
(upper part). Treatment of H1339 and MDA-MB-231 
tumor cells with 100 nM NVP-AUY922 did not affect 
the MICA and MICB cell surface density (MFI) (Fig. 1c, 
lower part). In contrast, NZ28 significantly reduced the 
MICA and MICB membrane expression (MFI) in both 
tumor cell lines. In T47D tumor cells which lack a MICA 
membrane expression, the MICB expression was found to 
be strongly reduced upon treatment with NZ28 (supple-
mentary Fig. 4).
In line with the membrane expression, the intracellu-
lar (ic) expression of MICA and MICB was significantly 
reduced in H1339 and MDA-MB-231 cells by NZ28 
(Fig. 1d). The Hsp90 inhibitor NVP-AUY922 did not affect 
the icMICA levels but increased the icMICB levels.
The activation of HSF1 by NVP-AUY922 and the inhi-
bition of HSF1 by NZ28 were proven by immunoblots 
and HSE-luciferase reporter assays. As expected, NVP-
AUY922 increased, whereas NZ28 decreased phospho-
rylated HSF1 at serine residue 326 (pHSF1 Ser326) and 
Hsp70 expression as well as HSF1 activity (Fig. 2, supple-
mentary Fig. 5).
HSF1 depletion mimics NZ28 by impairing NK 
cell-mediated lysis
To investigate whether an inhibition of HSF1 can explain 
the effects of NZ28 on the NK cell-mediated cytotoxic-
ity and MICA/B expression, we knocked down HSF1 in 
H1339 tumor cells by RNA interference. H1339 cells were 
infected either with a retrovirus encoding a specific shRNA 
against HSF1 (shHSF1) or with a control retrovirus (ctrl). 
The successful knockdown of HSF1 is shown in Fig. 3a. 
The HSF1 knockdown also strongly reduced the expres-
sion of Hsp70 (Fig. 3a) and of a HSE-luciferase reporter 
construct (Fig. 3b). Despite the HSF1 knockdown, tumor 
cell growth under standard cell culture conditions was not 
impaired (Fig. 3c).
To investigate whether depletion of HSF1 in H1339 
tumor cells affects NK cell-mediated cytotoxicity, control 
and HSF1 knockdown tumor cells were used as target cells 
for IL-2-activated NK cells. The cytotoxicity of stimulated 
Fig. 1  NZ28 impairs killing of tumor cells by activated NK cells. 
Tumor cells were treated with 2 or 20 µM NZ28 and/or 100 nM NVP-
AUY922 for 24 h. DMSO (0.2 %)-treated cells served as control. NK 
cells were stimulated for 4 days with 100 U/ml IL-2. a The expression 
of CD94, CD56 and NKG2D on NK cells was determined by FACS 
analysis. The fold increase in mean fluorescence intensity (MFI) of 
cell surface markers on stimulated compared to unstimulated NK 
cells is shown. Graphs represent mean values of seven independent 
experiments ±SEM. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. b The 
cytotoxicity of activated NK cells was measured after a 4-h co-incu-
bation with tumor cells by the CD107a degranulation assay. The rela-
tive cytotoxicity of activated NK cells incubated with differentially 
treated tumor cells compared to control cells is shown. Graphs rep-
resent mean values of 2–3 independent experiments ±SEM. White 
dots in the bar graphs indicate treatment of tumor cells with NVP-
AUY922. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. c Tumor cells were 
stained with antibodies against MICA/B or the respective isotype 
control. Representative FACS analysis shows MICA (left) and MICB 
(right) surface staining on tumor cells. The black solid lines represent 
MICA or MICB staining of control cells (ctrl; upper panels) or cells 
treated with 100 nM NVP-AUY922 (NVP; lower panels). The gray 
solid lines represent MICA or MICB staining of cells treated with 
20 µM NZ28 (NZ28; upper panels) or with 20 µM NZ28 plus 100 nM 
NVP-AUY922 (NZ28 + NVP; lower panels). Dotted lines represent 
the respective isotype controls. Graphs show mean values of at least 
two independent experiments ±SEM of the mean fluorescence inten-
sity (MFI) of MICA and MICB. White dots in the bar graphs indicate 
treatment of tumor cells with NVP-AUY922. *p ≤ 0.05, **p ≤ 0.01, 
***p ≤ 0.001. d The intracellular levels of MICA (icMICA, left) and 
MICB (icMICB, right) in tumor cells were determined by ELISA. 
The concentrations in the cell lysates were calculated relative to the 
total protein content of each sample. Graphs represent mean values 
of four independent experiments ±SEM. White dots in the bar graphs 
indicate treatment of tumor cells with NVP-AUY922. *p ≤ 0.05, 
**p ≤ 0.01, ***p ≤ 0.001
◂
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Fig. 2  NZ28 reduces Hsp70 expression and HSF1 activity. a Rep-
resentative HSF1 phospho S326 (pHSF1) and Hsp70 immunoblots 
of H1339 and MDA-MB-231 tumor cells treated with 20 µM NZ28 
and/or 100 nM NVP-AUY922 for 24 h. DMSO (0.2 %) treated cells 
served as control. b Luciferase assay of H1339 cells transfected with 
a HSF1 responsive firefly luciferase construct and treated with 20 µM 
NZ28 and/or 100 nM NVP-AUY922 for 24 h. DMSO (0.2 %)-treated 
cells served as control. White dots in the bar graphs indicate treat-
ment with NVP-AUY922. Graphs represent mean values ± SEM of 
at least three independent experiments. Significant differences are 
indicated (*p ≤ 0.05, **p ≤ 0.01)
Fig. 3  HSF1 depletion impairs lysis of H1339 tumor cells by acti-
vated NK cells. a Representative immunoblot showing the expression 
of HSF1, HSF1 phospho S326 (pHSF1), Hsp70 and ß-actin in H1339 
cells transfected with control (ctrl) or HSF1 shRNA (shHSF1). b 
Luciferase assay of H1339 ctrl and shHSF1 cells transfected with a 
HSF1 responsive firefly luciferase construct. Graphs represent mean 
values ± SEM of five experiments. Significant differences are indi-
cated (*p ≤ 0.05). c Growth curve of H1339 cells transfected with 
control (ctrl) or HSF1 shRNA (shHSF1). d NK cells from two dif-
ferent healthy donors were stimulated for 4 days with 100 U/ml IL-2. 
The cytotoxicity of IL-2-stimulated NK cells was measured after a 
4-h co-incubation with H1339 tumor cells transfected with control 
(ctrl) or HSF1 shRNA (shHSF1) by the CD107a degranulation assay. 
The relative cytotoxicity of NK cells incubated with shHSF1 cells 
compared to NK cells incubated with control tumor cells is shown 
for each NK cell donor. e NK cells were stimulated for 4 days with 
100 U/ml IL-2. The cytotoxicity of IL-2-stimulated NK cells was 
measured after a 4-h co-incubation with H1339 tumor cells trans-
fected with control (ctrl) or HSF1 shRNA (shHSF1) by europium 
assay. The cytotoxicity of stimulated NK cells against control tumor 
cells at an E:T (effector to target) ratio of 5:1 was set to one. Graphs 
represent mean values ± SEM of at least three independent experi-
ments. Significant differences between control and HSF1 knockdown 
cells are indicated (*p ≤ 0.05)
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NK cells against shHSF1 knockdown tumor cells was 
strongly reduced compared to control cells as demonstrated 
by degranulation (Fig. 3d) and europium assay (Fig. 3e). 
However, the reduction in NK cell-mediated lysis was 
much more pronounced after treatment of the H1339 tumor 
cells with NZ28 (Fig. 1b) compared to that of a HSF1 
knockdown (Fig. 3d).
HSF1 regulates MICB but not MICA expression
To ascertain whether the HSF1 knockdown has any impact 
on MICA/B levels, the membrane expression and ic expres-
sion of MICA/B were measured by FACS and ELISA, 
respectively. As shown in Fig. 4a, b, the HSF1 knockdown 
did not affect the MICA, but reduced the MICB surface 
Fig. 4  HSF1 knockdown reduces membrane and intracellular MICB 
levels. The expression of MICA and MICB on the membrane of 
H1339 tumor cells transfected with control (ctrl) or HSF1 shRNA 
(shHSF1) was determined by flow cytometry (a, b) and the intracel-
lular expression by ELISA (c). a Representative FACS analysis show-
ing MICA and MICB surface staining. The black solid lines represent 
MICA or MICB staining of control (ctrl) cells. The gray solid lines 
represent MICA or MICB staining of cells transfected with shRNA 
against HSF1 (shHSF1). Dotted lines represent the respective iso-
type controls. b The mean fluorescence intensity (MFI) of MICA and 
MICB on H1339 cells transfected with control (ctrl) or HSF1 shRNA 
(shHSF1) and treated with 20 µM NZ28 for 24 h is shown. Graphs 
represent mean values ± SEM of at least three independent experi-
ments. Significant differences are indicated (*p ≤ 0.05, **p ≤ 0.01, 
***p ≤ 0.001). c The intracellular levels of MICA (icMICA, left) and 
MICB (icMICB, right) of H1339 cells transfected with control (ctrl) 
or HSF1 shRNA (shHSF1) and treated with 20 µM NZ28 for 24 h 
were determined by ELISA. The concentrations in the cell lysates 
were calculated relative to the total protein content of each sample. 
Graphs represent mean values ± SEM of at least three independ-
ent experiments. Significant differences are indicated (*p ≤ 0.05, 
**p ≤ 0.01, ***p ≤ 0.001)
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density significantly. In line with the membrane expres-
sion, the ic MICB levels were significantly down-regulated 
by HSF1 knockdown, whereas the ic MICA expression 
remained unaffected (Fig. 4c). These data suggest that 
HSF1 regulates the transcription of MICB but not that of 
MICA.
NZ28 inhibits activity of the MICA/B transcription factors 
NF-κB and Sp1
Although HSF1 knockdown only diminished the MICB 
expression in H1339 cells, NZ28 strongly reduced the 
ic and membrane MICA and MICB expression in con-
trol as well as in HSF1 knockdown cells (Fig. 4b, c). 
Therefore, we asked the question whether other tran-
scription factors that have been described to regulate 
the transcription of MICA/B might also be affected by 
NZ28. As shown by the luciferase assay, NZ28 inhibited 
not only the transcriptional activity of HSF1 but also 
that of NF-κB and Sp1 in H1339 and T47D tumor cells 
(Fig. 5).
Discussion
Targeting the heat shock response (Hsp70 or its main tran-
scription factor HSF1) by small molecules or RNA inter-
ference has been shown to sensitize tumor cells to Hsp90 
inhibition [1–5]. Previous work of our group revealed that 
HSF1 inhibition by NZ28 increases the radiosensitizing 
efficiency of the Hsp90 inhibitor NVP-AUY922 in lung 
and breast cancer cell lines (unpublished data). In recent 
years, evidence has accumulated that not only the inter-
play between radio- and chemotherapy, but also the host 
immune system plays an important role in determining 
the clinical outcome of cancer patients [23]. Radiochemo-
therapy has been reported to affect the antigen expression 
on tumor cells and the secretion of soluble factors that con-
tribute to immune stimulation [24]. Lung and breast tumors 
are frequently treated with radiotherapy, and NK cells have 
been documented to be critically involved in anti-tumor 
immunity against these very common tumor entities [25, 
26]. Therefore, in this study, we investigated the effects of 
this novel combined treatment modality (NZ28 and NVP-
AUY922) with respect to NK cell cytotoxicity and NK cell 
ligand expression on lung and breast tumor cells.
Whereas NVP-AUY922 was shown to increase the 
activity of HSF1 and the icMICB expression, it did not 
alter the icMICA expression, suggesting that MICA is not 
regulated by HSF1 in our investigated cell lines. Indeed, 
HSF1 knockdown reduced the expression of MICB but not 
that of MICA. In line with our results, Venkataraman et al. 
[12] have shown that MICA is less inducible by stress than 
MICB due to a weaker binding capacity of HSF1 to the 
HSE.
In contrast to icMICB, the MICB cell surface density 
was not increased by NVP-AUY922. This might be due to 
a default in the membrane translocation of MICB. Consist-
ently, the sensitivity of tumor cells toward NK cell-medi-
ated lysis was not improved. Other groups demonstrated 
that high concentrations of the Hsp90 inhibitor 17-AAG 
(1 and 6 µM) up-regulate the cell surface density of MICA 
and MICB on multiple myeloma cells and Hodgkin’s lym-
phoma cells and thereby can enhance NK cell cytotoxic-
ity [6, 7]. The discrepancy to their results might be either 
explained by differences in the tumor cell lines or by the 
lower and more physiological concentration of the Hsp90 
inhibitor used in our study.
NZ28 down-regulated the HSF1 activity and the MICA/B 
expression on lung and mammary tumor cells, and this cor-
related with a reduced sensitivity to NK cell-mediated lysis. 
As NZ28 treatment also reduced the MICA and MICB 
expression in HSF1-depleted cells, we assume that NZ28 
exerts its effects on MICA/B expression not only via HSF1. 
Luciferase reporter assays revealed that the activity of other 
Fig. 5  NZ28 reduces NF-κB and SP1 transcriptional activity in 
tumor cells. H1339 and T47D cells were transfected with reporter 
plasmids that contain NF-κB and SP1 responsive firefly lucif-
erase constructs and treated with 20 µM NZ28 for 24 h. DMSO 
(0.2 %)-treated cells served as control (0 µM NZ28). Mean val-
ues ± SEM of two independent experiments (each measured in dupli-
cate) are presented. Significant differences are indicated (*p ≤ 0.05, 
**p ≤ 0.01, ***p ≤ 0.001)
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transcription factors such as Sp1 and NF-κB was also inhib-
ited by NZ28. In line with our results, treatment of Hela cells 
with a NF-κB inhibitor also reduced the MICA expression 
[27]. In contrast, in Jurkat cells NF-κB down-regulation by 
siRNA did not modify the MICA/B expression but silencing 
of Sp1 reduced the MICA/B expression [14].
Like NZ28, the naturally derived compound trip-
tolide has originally been shown to inhibit the heat shock 
response [28]. Later on, Banerjee et al. [29] demonstrated 
that triptolide reduces the activity of Sp1 and this in turn 
leads to decreased HSF1 and NF-κB activities. By silenc-
ing Sp1, they could clearly show that Sp1 is a master 
regulator for HSF1 and NF-κB. Therefore, we propose 
that NZ28 might inhibit the transcriptional activity of Sp1 
which in turn results in a reduced HSF1 and NF-κB activ-
ity. Subsequently, this leads to the down-regulation of both 
MICA and MICB which causes a complete loss in NK cell-
mediated killing.
In summary, our data reveal that HSF1 activation by 
NVP-AUY922 neither affects MICA/B surface density nor 
affects the associated NK cell cytotoxicity (Fig. 6). How-
ever, HSF1 depletion decreases the MICB but not MICA 
membrane expression and thereby leads to a reduction 
in the NK cell-mediated cytotoxicity. In contrast, NZ28 
severely blocks NK cell-mediated cytotoxicity by a sub-
stantial down-regulation of both NK2D ligands, MICA and 
MICB. This effect might be explained by the fact that NZ28 
impairs not only HSF1 but also Sp1 and NF-κB activities.
Despite these negative effects of NZ28 on the function 
of NK cells, NZ28 has been shown to be very efficient in 
sensitizing tumor cells toward radiation (unpublished data) 
and chemotherapy [5].
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